![Cagrilintide [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/cagrilitinde.jpg)
$80.00
Cagrilintide is an investigational long-acting amylin analogue studied for appetite and weight-related outcomes. It is not FDA-approved, and combination-trial results for CagriSema do not represent cagrilintide alone. Research use only; not for human or animal consumption.
For laboratory research only. Not for human or animal consumption.
VIP Peptides Ā· Investigational Compound
Cagrilintide is a long-acting synthetic analogue of amylin, a hormone
released by pancreatic beta cells. It is being studied on its own and
in combination with semaglutide as CagriSema. Cagrilintide remains
investigational and is not FDA-approved.
Product Information
Cagrilintide is a synthetic, long-acting analogue of amylin, a
37-amino-acid hormone co-released with insulin by pancreatic beta
cells. It was developed with structural modifications intended to
extend its activity.
Cagrilintide is studied as a dual amylin and calcitonin receptor
agonist. Research has examined its effects on satiety, food intake
and gastric emptying. These mechanisms and trial findings do not
establish a treatment benefit for an unapproved research product.
CagriSema is a separate investigational combination of cagrilintide
and semaglutide. Results from that combination should not be
presented as results from cagrilintide alone.
| Product | Cagrilintide |
|---|---|
| Compound type | Synthetic amylin analogue |
| Receptor activity | Amylin and calcitonin receptor research |
| Developer | Novo Nordisk |
| Combination under study | CagriSema: cagrilintide plus semaglutide |
| Regulatory status | Investigational; not FDA-approved |
| Use classification | Research use only |
Research Areas
Clinical and preclinical research has examined cagrilintideās
effects on satiety, appetite and body weight. Proposed receptor
activity does not confirm an outcome for an individual or
unapproved product.
In the phase 3 REDEFINE 1 trial, the cagrilintide-alone group had
an estimated mean body-weight reduction of about 11.8% at 68 weeks
under the trialās treatment conditions. A clinical-trial result
does not establish efficacy or safety for research-grade material.
In REDEFINE 1, the cagrilintideāsemaglutide combination produced
greater average weight reduction than placebo. This combination
result cannot be attributed to cagrilintide alone or transferred
to a different product.
Evidence Overview
Clinical trials have studied cagrilintide alone and in combination
with semaglutide. Trial results apply to the specific investigational
products, participants and conditions studied.
CagriSemaās reported results are combination-treatment findings.
They should not be used to claim that cagrilintide alone produces
the same outcomes. Research-grade products are not equivalent to
the controlled trial formulations.
Safety & Regulatory Status
Gastrointestinal effects reported in clinical studies include nausea,
vomiting, constipation, diarrhea and abdominal discomfort. Injection
site reactions may also occur. Safety and tolerability depend on the
specific investigational product and clinical context.
As of October 15, 2026, cagrilintide alone is not FDA-approved.
Novo Nordisk submitted an application for CagriSema in December 2025;
the combination remained investigational while FDA review was
anticipated in late 2026.
FDA states that cagrilintide cannot be used in compounding under
federal law. A research-grade vial is not an FDA-approved medicine
and should not be represented as a compounded or approved treatment.
Age & Policy Confirmation
Please confirm your age and review the policies before entering.
![AOD-9604 (Anti-Obesity Drug 9604) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/aod9604-300x300.jpg)
![TB500 Thymosin B4 [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/thy-300x300.jpg)
![Ipamorelin [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/ipamorelin-300x300.jpg)
Reviews
There are no reviews yet.